Facebook
Twitter
LinkedIn
ForwardApplication of Individualized Treatment Strategies for CLL/SLL
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.
Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC
Target Audience
This educational program is intended for physicians, physician associates/physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Design treatment plans for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, biomarkers, comorbidities, and patient preference
- Appraise intraclass differences among agents with the similar therapeutic target in CLL/SLL, regarding selectivity, target binding, efficacy, and adverse event profiles
- Develop strategies to address unique clinical challenges and leverage an understanding of the current data and NCCN Guideline to optimize outcomes for patients with CLL/SLL
- Evaluate the evolving role of measurable residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy
Farrukh T. Awan, MD
UT Southwestern Simmons Comprehensive Cancer Center
Asher Chanan-Khan, MBBS, MD
Mayo Clinic Cancer Center
William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Farrukh Awan, MD
AbbVie: Consulting Fee
AbbVie/Pharmacyclics: Grant/Research Support
ADC Therapeutics: Consulting Fee
AstraZeneca: Consulting Fee
BeiGene: Consulting Fee
Bristol Myers Squibb: Consulting Fee
Cardinal Health: Consulting Fee
Caribou: Consulting Fee
Celgene: Consulting Fee
Dava Oncology: Consulting Fee
Epizyme: Consulting Fee
Genentech: Consulting Fee
Gilead Sciences: Consulting Fee
Incyte: Consulting Fee
Janssen: Consulting Fee
Johnson & Johnson: Consulting Fee
Karyopharm: Consulting Fee
Kite Pharma: Consulting Fee
MEI Pharma: Consulting Fee
Merck: Consulting Fee
Pharmacyclics: Consulting Fee
Verastem: Consulting Fee
Asher Chanan-Khan, MBBS, MD
AbbVie: Grant/Research Support; Honoraria
Ascentage: Consulting Fee; Grant/Research Support
BeiGene: Consulting Fee; Grant/Research Support
Cellectar: Consulting Fee
Janssen: Grant/Research Support
Starton: Consulting Fee
William G. Wierda, MD, PhD
AbbVie: Grant/Research Support
AstraZeneca/Acerta: Grant/Research Support
Cyclacel: Grant/Research Support
Genentech: Grant/Research Support
Gilead: Grant/Research Support
GlaxoSmithKline/Novartis: Grant/Research Support
Janssen: Grant/Research Support
Juno: Grant/Research Support
Kite: Grant/Research Support
Loxo Oncology/Lilly: Grant/Research Support
Miragen: Grant/Research Support
Oncternal Therapeutics: Grant/Research Support
Pharmacyclics: Grant/Research Support
Sunesis: Grant/Research Support
Xencor: Grant/Research Support
NCCN and CCO Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 2.0 contact hours.
Pharmacists
NCCN designates this application-based continuing education activity for 2.0 contact hours (0.20 CEUs) of continuing education credit. UAN: JA4008196-0000-22-088-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until July 14, 2023. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 2.00 AAPA Category 1 CME credit
- 2.00 ACPE contact hours
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC contact hours
- 2.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing